ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1546

Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus

Ricardo Blanco1, Iñigo Rúa-Figueroa2, Roser Solans3, Maria C Cid4, Marina Blanco5, Ismael Garcia Moguel6, Francisco Perez Grimaldi7, Ana Noblejas8, Moises Labrador3, Cristian Domingo9, Georgina espigol10, Fernando Sanchez Toril11, Francisco Ortiz-Sanjuán12, Ebymar Arismendi13 and Jose María Alvaro-Gracias14, 1Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 2Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, 3Internal Medicine Department, H. Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, 4Hospital Clinic Barcelona, Barcelona, Spain, 5Pneumology Department, Hospital Universitario de A Coruña, Madrid, Spain, 6Allergy Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain, 7Pneumology Department, H. University of Jerez, Cádiz, Spain, 8Internal Medicine Department, Hospital Universitario La Paz, Madrid, Spain, 9Pneumology Department, Corporació Sanitaria Parc Taulí, Universitat Autònoma de Barcelona, Barcelona, Spain, 10Autoimmune Diseases Department, Hospital Clínic, FCRB-IDIBAPS, Universitat de Barcelona, Barcelona, Spain, 11Pneumology Department, Hospital Arnau Vilanova, Valencia, Spain;, Valencia, Spain, 12Hospital Universitario y Politécnico La Fe, Valencia, Spain, 13Pneumology Department, Hospital Clínic de Barcelona, Barcelona, Spain, Universitat de Barcelona, Spain and CIBERES, Barcelona, Spain, 14Hospital General Universitario Gregorio Marañon, Madrid, Spain

Meeting: ACR Convergence 2023

Keywords: Diagnostic criteria, Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss), Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1534–1553) Vasculitis – ANCA-Associated Poster II: Epidemiology, Outcomes, & Classification

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare ANCA-associated vasculitis, characterized histologically by eosinophilic tissue infiltration, necrotizing vasculitis, and eosinophil-rich granulomatous inflammation.

The diagnosis of EGPA is often challenging due to its rarity, heterogeneous and multiorgan clinical presentation, and the overlapping with other vasculitis or eosinophilic disorders. The identification of suspicion signals of EGPA addresses a fundamental practical barrier in achieving timely diagnosis for patients with this rare but potentially devastating disease.

Our purpose was to identify a comprehensive and evidence-based checklist of signs, symptoms and laboratory parameters reported to precede the diagnosis of EGPA that can be used as red flags, raising the suspicion and prompt the performance of appropriate confirmatory tests.

Methods: A systematic literature search strategy was developed to identify signs, symptoms and laboratory abnormalities that should raise the suspicion of a possible EGPA patient. GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology was used to assess the quality of the scientific evidence supporting each criterion.

A multidisciplinary nominal group consensus approach (including rheumatologists, internal medicine specialists, pulmonologists, and allergists) was established for the development of the expert consensus.

Red flags identified as suspicion signals for EGPA were categorized by organ system, manifestation, and laboratory test to facilitate rational, evidence-based clinical review of patients presenting with eosinophilia.

Results: A total of 382 records were identified and reviewed, and 85 studies were included in the literature review (Figure 1). From these 85 publications a total of 214 items were assessed and 40 red flags were identified as relevant to raise a suspicion of EGPA. As the publications were derived from observational studies the GRADE level of evidence was low.

Using these 40 red flags, an evidence-based clinical checklist tool was developed for use in routine practice to raise EGPA suspicion in patients with eosinophilia (peripheral blood eosinophil count >1 x 109/L, with no treatment that could explain an alteration of this value) (Table 1).

Conclusion: Systematic literature review, multidisciplinary expert consensus rating and GRADE methodology has enabled, for the first time, the identification of a comprehensive set of red flags that could be used to raise a suspicion for EGPA, providing clinicians with an evidence-based checklist tool that can be integrated into their routine practice.

Supporting image 1

Figure 1. PRISMA flowchart for the systematic literature review.

Supporting image 2

TABLE 1. EGPA suspicion red flags


Disclosures: R. Blanco: AbbVie, 5, 6, Amgen, 6, AstraZeneca, 2, BMS, 6, Eli Lilly, 6, Galapagos, 2, 6, Janssen, 2, 6, MSD, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 5, 6, Sanofi, 6; I. Rúa-Figueroa: AstraZeneca, 5, GSK, 1, 6; R. Solans: CSL-Vifor, 6, GSK, 1, 6; M. Cid: AbbVie/Abbott, 1, 2, 6, AstraZeneca, 1, GSK, 1, 2, 6, Kininksa Pharmaceutical, 5, SCL-Vifor, 2, 6; M. Blanco: None; I. Garcia Moguel: AstraZeneca, 1, 2, 5, 6, GSK, 1, 2, 5, 6, Sanofi, 1, 2, 5, 6, Teva Therapeutics, 1, 2, 5, 6; F. Perez Grimaldi: AstraZeneca, 6, Chiesi, 6, GSK, 6, Novartis, 6, Sanofi, 6, Teva Therapeutics, 6; A. Noblejas: CSL-Vifor, 6, GSK, 1, 6; M. Labrador: AstraZeneca, 6, GSK, 1, 6, Novartis, 6, Sanofi, 6; C. Domingo: ALK, 1, 2, 5, 6, AstraZeneca, 1, 2, 5, 6, Chiesi, 1, 2, 5, 6, GSK, 1, 2, 6, Menarini, 12, Travel fees, Novartis, 1, 2, 5, 6, Sanofi, 1, 2, 5, 6, Teva Therapeutics, 1, 2, 5, 6; G. espigol: CSl-Vifor, 1, GSK, 1; F. Sanchez Toril: None; F. Ortiz-Sanjuán: Eli Lilly, 6, Grunenthal, 2, GSK, 2; E. Arismendi: AstraZeneca, 6, GebroPharna, 6, GSK, 6, Merck/MSD, 6, Sanofi, 1; J. Alvaro-Gracias: Abbvie, 2, 6, AstraZeneca, 2, 6, Eli Lilly, 2, 6, Galapagos, 2, 6, Gilead, 2, 6, GSK, 2, 6, Merck/MSD, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, UCB, 2, 6.

To cite this abstract in AMA style:

Blanco R, Rúa-Figueroa I, Solans R, Cid M, Blanco M, Garcia Moguel I, Perez Grimaldi F, Noblejas A, Labrador M, Domingo C, espigol G, Sanchez Toril F, Ortiz-Sanjuán F, Arismendi E, Alvaro-Gracias J. Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/eosinophilic-granulomatosis-with-polyangiitis-clinical-suspicion-red-flags-identification-by-a-systematic-literature-review-and-multidisciplinary-expert-consensus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/eosinophilic-granulomatosis-with-polyangiitis-clinical-suspicion-red-flags-identification-by-a-systematic-literature-review-and-multidisciplinary-expert-consensus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology